Vaccitech plc (VACC): Price and Financial Metrics

Vaccitech plc (VACC): $4.56

0.31 (+7.29%)

POWR Rating

Component Grades













Add VACC to Watchlist
Sign Up

Industry: Biotech



in industry

VACC Stock Price Chart Interactive Chart >

Price chart for VACC

VACC Price/Volume Stats

Current price $4.56 52-week high $17.99
Prev. close $4.25 52-week low $2.97
Day low $4.29 Volume 1,800
Day high $4.56 Avg. volume 23,800
50-day MA $5.05 Dividend yield N/A
200-day MA $10.41 Market Cap 169.59M

Vaccitech plc (VACC) Company Bio

Vaccitech plc is a clinical-stage biopharmaceutical company that engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. Its therapeutic programs include VTP-300, indicated for the treatment of chronic hepatitis B infection; VTP-200, indicated for the treatment of human papilloma virus infection; VTP-850, indicated for the treatment of prostate cancer; and VTP-600, indicated for the treatment of non-small cell lung cancer. The company's prophylactic programs include VTP-400 for the prevention of herpes zoster or shingles; and VTP-500 for the prevention of Middle East respiratory syndrome. In addition, it is developing AZD1222, a COVID-19 vaccine. Vaccitech plc was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc on March 31, 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, United Kingdom.

VACC Latest News Stream

Event/Time News Detail
Loading, please wait...

VACC Latest Social Stream

Loading social stream, please wait...

View Full VACC Social Stream

Latest VACC News From Around the Web

Below are the latest news stories about Vaccitech plc that investors may wish to consider to help them evaluate VACC as an investment opportunity.

DeepMind Co-Founder Suleyman Exits Google for VC Firm Greylock

(Bloomberg) -- The co-founder of Google’s high-profile DeepMind artificial intelligence lab has left Alphabet Inc. to join venture capital firm Greylock Partners, following a turbulent tenure.Most Read from BloombergStock Rebound Fails and Futures Plunge on Earnings: Markets WrapA Nor’easter Approaching New York Risks Becoming a Bomb CycloneMark Zuckerberg’s Stablecoin Ambitions Unravel With Diem Sale TalksNvidia Quietly Prepares to Abandon $40 Billion Arm BidTech Giants Rally Amid Bullish Outlo

Yahoo | January 21, 2022

Vaccitech Plc (VACC) Gets a Buy Rating from H.C. Wainwright

In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Vaccitech Plc (VACC – Research Report), with a price target of $23.00. The company's shares closed last Tuesday at $9.98. According to, Chen is a 5-star analyst with an average return of 24.0% and a 37.4% success rate. Chen covers the Healthcare sector, focusing on stocks such as Ortho Clinical Diagnostics Holdings, Interpace Diagnostics Group, and HTG Molecular Diagnostics. Currently, the analyst consensus on Vaccitech Plc is a Moderate Buy with an average price target of $23.00.

Christine Brown on TipRanks | January 19, 2022

Vaccitech, Cancer Research UK, Ludwig begins dosing in phase 1/2a lung cancer trial

Cancer Research UK, Vaccitech (VACC) and the Ludwig Institute for Cancer Research said the first patient was dosed in a phase 1/2a trial called MAGE trial evaluating

Seeking Alpha | January 18, 2022

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

OXFORD, United Kingdom, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Cancer Research UK, Vaccitech plc (Nasdaq: VACC) and the Ludwig Institute for Cancer Research (Ludwig), today announce the first patient dosed in the MAGE trial, which is testing a novel immunotherapeutic, VTP-600, in patients with the most common type of lung cancer. The phase I/IIa trial is expected to enroll approximately 86 people who have been newly diagnosed with non-small cell lung cancer (NSCLC) and will be testing the safety and

Yahoo | January 18, 2022

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

OXFORD, United Kingdom, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Vaccitech plc ("Vaccitech"), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines, today announced it will host a virtual Key Opinion Leader ("KOL") event on VTP-300, in development as a key component of a functional cure therapy for chronic hepatitis B (CHB) infection, and the broader CHB therapeutics landscape. The event will be webcast live on January 25 th at 8:30 a.m. EST. Featured speakers: Dr. Kaushik Agarwal, consultant hepatologist and transplant physician at the Institute of Liver Studies at King''s College Hospital, Viral Hepatitis Service lead, and Director of the NIHR South London Clinical Research Network. Dr. Henry L. Y. Chan, head of the Divis...

Benzinga | January 13, 2022

Read More 'VACC' Stories Here

VACC Price Returns

1-mo -14.29%
3-mo N/A
6-mo -65.06%
1-year -68.72%
3-year N/A
5-year N/A
YTD -58.96%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7396 seconds.